In the latter study, however, combination of the HER2 TKI with the PI3K inhibitor was not able to induce tumor regression, whereas combination of a PI3K p110 inhibitor (BKM120) with trastuzumab did result in tumor regression, albeit in a wild-type PIK3CA model. The gene discussed is ERBB2; the disease is neoplasm.